
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5995621/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Banff 97 working classification of renal allograft pathology. Kidney International, 1999, 55, 713-723.	5.2	2,817
2	Antibody-Mediated Rejection Criteria - an Addition to the Banff '97 Classification of Renal Allograft Rejection. American Journal of Transplantation, 2003, 3, 708-714.	4.7	960
3	Polyomavirus-Associated Nephropathy in Renal Transplantation: Interdisciplinary Analyses and Recommendations. Transplantation, 2005, 79, 1277-1286.	1.0	842
4	Tolerogenic immunosuppression for organ transplantation. Lancet, The, 2003, 361, 1502-1510.	13.7	478
5	HUMAN POLYOMA VIRUS-ASSOCIATED INTERSTITIAL NEPHRITIS IN THE ALLOGRAFT KIDNEY1. Transplantation, 1999, 67, 103-109.	1.0	465
6	The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell– and antibody-mediated rejection. American Journal of Transplantation, 2020, 20, 2318-2331.	4.7	437
7	<scp>BK</scp> polyomavirus in solid organ transplantation—Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clinical Transplantation, 2019, 33, e13528.	1.6	257
8	Correlates of Quantitative Measurement of BK Polyomavirus (BKV) DNA with Clinical Course of BKV Infection in Renal Transplant Patients. Journal of Clinical Microbiology, 2004, 42, 1176-1180.	3.9	216
9	Sensitization in Transplantation: Assessment of Risk (STAR) 2017 Working Group Meeting Report. American Journal of Transplantation, 2018, 18, 1604-1614.	4.7	205
10	Expression of Epstein–Barr Virus–Encoded Small RNA (by the EBER-1 Gene) in Liver Specimens from Transplant Recipients with Post-Transplantation Lymphoproliferative Disease. New England Journal of Medicine, 1992, 327, 1710-1714.	27.0	202
11	Nephropathy Due to Polyomavirus Type BK. New England Journal of Medicine, 2000, 342, 1361-1363.	27.0	201
12	BK virus infection in a kidney allograft diagnosed by needle biopsy. American Journal of Kidney Diseases, 1995, 26, 671-673.	1.9	196
13	A schema for histologic grading of small intestine allograft acute rejection. Transplantation, 2003, 75, 1241-1248.	1.0	182
14	Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. Journal of the American College of Surgeons, 2005, 200, 505-515.	0.5	167
15	POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS IN ADULT AND PEDIATRIC RENAL TRANSPLANT PATIENTS RECEIVING TACROLIMUS-BASED IMMUNOSUPPRESSION1. Transplantation, 1999, 68, 1851-1854.	1.0	153
16	BIOPSY OF MARGINAL DONOR KIDNEYS: CORRELATION OF HISTOLOGIC FINDINGS WITH GRAFT DYSFUNCTION1. Transplantation, 2000, 69, 1352-1357.	1.0	141
17	The Clinical Spectrum, Pathology, and Clonal Analysis of Epstein-Barr Virus–Associated Lymphoproliferative Disorders in Heart–Lung Transplant Recipients. American Journal of Clinical Pathology, 1989, 92, 177-185.	0.7	140
18	Effect of Leflunomide and Cidofovir on Replication of BK Virus in an In Vitro Culture System. Transplantation, 2005, 79, 116-118.	1.0	133

#	Article	IF	CITATIONS
19	The Banff Working Group Classification of Definitive Polyomavirus Nephropathy: Morphologic Definitions and Clinical Correlations. Journal of the American Society of Nephrology: JASN, 2018, 29, 680-693.	6.1	129
20	Long-term kidney transplant survival. American Journal of Kidney Diseases, 2001, 38, S44-S50.	1.9	121
21	HLA Mismatching Increases the Risk of BK Virus Nephropathy in Renal Transplant Recipients. American Journal of Transplantation, 2004, 4, 1691-1696.	4.7	112
22	A PROSPECTIVE, RANDOMIZED TRIAL OF TACROLIMUS/PREDNISONE VERSUS TACROLIMUS/PREDNISONE/MYCOPHENOLATE MOFETIL IN RENAL TRANSPLANT RECIPIENTS*. Transplantation, 1999, 67, 411-415.	1.0	112
23	Molecular genotyping of BK and JC viruses in human polyomavirus[ndash]associated interstitial nephritis after renal transplantation. American Journal of Kidney Diseases, 2001, 38, 354-365.	1.9	111
24	TACROLIMUS RESCUE THERAPY FOR RENAL ALLOGRAFT REJECTION-FIVE-YEAR EXPERIENCE1. Transplantation, 1997, 63, 223-228.	1.0	108
25	RENAL TRANSPLANTATION IN RECIPIENTS OVER THE AGE OF 60. Transplantation, 1999, 67, 1191-1193.	1.0	108
26	Distribution patterns of BK polyomavirus (BKV) subtypes and subgroups in American, European and Asian populations suggest co-migration of BKV and the human race. Journal of General Virology, 2009, 90, 144-152.	2.9	97
27	Successful Treatment of BK Viremia Using Reduction in Immunosuppression Without Antiviral Therapy. Transplantation, 2008, 85, 850-854.	1.0	96
28	Serum analysis after transplant nephrectomy reveals restricted antibody specificity patterns against structurally defined HLA class I mismatches. Transplant Immunology, 2005, 14, 53-62.	1.2	95
29	Rationale and design of the Kidney Precision Medicine Project. Kidney International, 2021, 99, 498-510.	5.2	94
30	Kidney Transplantation Under a Tolerogenic Regimen of Recipient Pretreatment and Low-Dose Postoperative Immunosuppression With Subsequent Weaning. Annals of Surgery, 2003, 238, 520-525.	4.2	93
31	Pathogenesis and Management of Polyomavirus Infection in Transplant Recipients. Clinical Infectious Diseases, 2002, 35, 1081-1087.	5.8	90
32	Quantitation of viral DNA in renal allograft tissue from patients with BK virus nephropathy1. Transplantation, 2002, 74, 485-488.	1.0	90
33	A comparative study of BK and JC virus infections in organ transplant recipients. Journal of Medical Virology, 2005, 77, 238-243.	5.0	90
34	An Analysis of Early Renal Transplant Protocol Biopsies - the High Incidence of Subclinical Tubulitis. American Journal of Transplantation, 2001, 1, 47-50.	4.7	88
35	B cells mediate chronic allograft rejection independently of antibody production. Journal of Clinical Investigation, 2014, 124, 1052-1056.	8.2	85
36	Pulmonary Blastoma: An Immunohistochemical Analysis with Comparison with Fetal Lung in Its Pseudoglandular Stage. American Journal of Clinical Pathology, 1990, 93, 167-175.	0.7	84

#	Article	IF	CITATIONS
37	ROLE OF DONOR KIDNEY BIOPSIES IN RENAL TRANSPLANTATION. Transplantation, 2001, 71, 1361-1365.	1.0	83
38	REVERSAL OF STEROID- AND ANTI-LYMPHOCYTE ANTIBODY- RESISTANT REJECTION USING INTRAVENOUS IMMUNOGLOBULIN (IVIG) IN RENAL TRANSPLANT RECIPIENTS. Transplantation, 2001, 72, 419-422.	1.0	83
39	Neutralization Serotyping of BK Polyomavirus Infection in Kidney Transplant Recipients. PLoS Pathogens, 2012, 8, e1002650.	4.7	83
40	Management and Outcome of BK Viremia in Renal Transplant Recipients. Transplantation, 2012, 94, 814-821.	1.0	83
41	JC VIRUS INFECTION IN ALLOGRAFT KIDNEYS. Transplantation, 2001, 71, 1300-1303.	1.0	81
42	Retransplantation in patients with graft loss caused by polyoma virus nephropathy. Transplantation, 2004, 77, 131-133.	1.0	81
43	Viral regulatory region sequence variations in kidney tissue obtained from patients with BK virus nephropathy. Kidney International, 2003, 64, 743-747.	5.2	79
44	Polyomavirus Allograft Nephropathy: Sequential Assessment of Histologic Viral Load, Tubulitis, and Graft Function Following Changes in Immunosuppression. American Journal of Transplantation, 2003, 3, 1378-1382.	4.7	78
45	Ether Lipid Ester Derivatives of Cidofovir Inhibit Polyomavirus BK Replication In Vitro. Antimicrobial Agents and Chemotherapy, 2006, 50, 1564-1566.	3.2	75
46	Lymphoma resembling hodgkin disease after posttransplant lymphoproliferative disorder in a liver transplant recipient. Cancer, 1993, 72, 2568-2573.	4.1	72
47	BK virus–associated urinary bladder carcinoma in transplant recipients: report of 2 cases, review of the literature, and proposed pathogenetic model. Human Pathology, 2013, 44, 908-917.	2.0	70
48	DNA sequencing of viral capsid protein VP-1 region in patients with BK virus interstitial nephritis. Transplantation, 2002, 73, 1090-1094.	1.0	69
49	CLINICAL SIGNIFICANCE OF RENAL ALLOGRAFT BIOPSIES WITH ???BORDERLINE CHANGES,??? AS DEFINED IN THE BANFF SCHEMA1. Transplantation, 1997, 64, 992-995.	1.0	67
50	Anti-BK Virus Activity of Ciprofloxacin and Related Antibiotics. Clinical Infectious Diseases, 2005, 41, 1366-1367.	5.8	66
51	Polyomavirus BK Neutralizing Activity in Human Immunoglobulin Preparations. Transplantation, 2010, 89, 1462-1465.	1.0	66
52	The Banff 2009 Working Proposal for Polyomavirus Nephropathy: A Critical Evaluation of Its Utility as a Determinant of Clinical Outcome. American Journal of Transplantation, 2012, 12, 907-918.	4.7	64
53	Monitoring for Polyomavirus BK And JC in Urine: Comparison of Quantitative Polymerase Chain Reaction with Urine Cytology. Transplantation, 2005, 79, 984-986.	1.0	60
54	Glomerular changes in BK virus nephropathy. Human Pathology, 2004, 35, 367-370.	2.0	59

#	Article	IF	CITATIONS
55	Correlation of histologic findings on preimplant biopsy with kidney graft survival. Transplant International, 2008, 21, 892-898.	1.6	59
56	Herpesvirus 6 Variant A Infection After Heart Transplantation with Giant Cell Transformation in Bile Ductular and Gastroduodenal Epithelium. American Journal of Surgical Pathology, 1997, 21, 847-853.	3.7	59
57	Monitoring of human liver and kidney allograft tolerance: a tissue/histopathology perspective. Transplant International, 2009, 22, 120-141.	1.6	57
58	Tacrolimus (FK506)-Associated Renal Pathology. Advances in Anatomic Pathology, 1997, 4, 265.	4.3	55
59	Genotyping Schemes for Polyomavirus BK, Using Gene-Specific Phylogenetic Trees and Single Nucleotide Polymorphism Analysis. Journal of Virology, 2009, 83, 2285-2297.	3.4	55
60	Phylogenetic Analysis of Polyomavirus BK Sequences. Journal of Virology, 2006, 80, 8869-8879.	3.4	54
61	Quantitation of DNA of Polyomaviruses BK and JC in Human Kidneys. Journal of Infectious Diseases, 2005, 192, 504-509.	4.0	52
62	Commercially Available Immunoglobulins Contain Virus Neutralizing Antibodies Against All Major Genotypes of Polyomavirus BK. American Journal of Transplantation, 2015, 15, 1014-1020.	4.7	50
63	Short-term adverse effects of early subclinical allograft inflammation in kidney transplant recipients with a rapid steroid withdrawal protocol. American Journal of Transplantation, 2018, 18, 1710-1717.	4.7	50
64	Long-Term Effects of Alemtuzumab on Regulatory and Memory T-Cell Subsets in Kidney Transplantation. Transplantation, 2012, 93, 813-821.	1.0	49
65	Inhibitory Interactions between BK and JC Virus among Kidney Transplant Recipients. Journal of the American Society of Nephrology: JASN, 2011, 22, 825-831.	6.1	48
66	Clinical significance of the distribution of C4d deposits in different anatomic compartments of the allograft kidney. Modern Pathology, 2008, 21, 1490-1498.	5.5	47
67	Emerging role of donor-specific anti–human leukocyte antigen antibody determination for clinical management after solid organ transplantation. Human Immunology, 2009, 70, 645-650.	2.4	47
68	Results of Repeat Renal Transplantation After Graft Loss From BK Virus Nephropathy. Transplantation, 2011, 92, 781-786.	1.0	47
69	Immunoglobulin G, A, and M Responses to BK Virus in Renal Transplantation. Vaccine Journal, 2006, 13, 1057-1063.	3.1	45
70	Impact of Genomic Sequence Variability on Quantitative PCR Assays for Diagnosis of Polyomavirus BK Infection. Journal of Clinical Microbiology, 2011, 49, 4072-4076.	3.9	45
71	Donor and Recipient BKV-Specific IgG Antibody and Posttransplantation BKV Infection. Transplantation, 2013, 95, 896-902.	1.0	44
72	Lymphocyte subsets in granulomas of human tuberculosis: An in situ immunofluorescence study using monoclonal antibodies. Pathology, 1990, 22, 153-155.	0.6	43

#	Article	IF	CITATIONS
73	Minimal Evidence of Transdifferentiation from Recipient Bone Marrow to Parenchymal Cells in Regenerating and Long-Surviving Human Allografts. American Journal of Transplantation, 2003, 3, 1173-1181.	4.7	43
74	Helicobacter pylori May Play a Contributory Role in the Pathogenesis of Primary Sclerosing Cholangitis. Digestive Diseases and Sciences, 2007, 52, 2265-2270.	2.3	42
75	???SUBOPTIMAL??? KIDNEY DONORS. Transplantation, 1996, 62, 1242-1246.	1.0	42
76	Adenovirus Hepatitis In The Adult Allograft Liver1. Transplantation, 1997, 64, 1483-1485.	1.0	42
77	Measurements of Global Cell-Mediated Immunity in Renal Transplant Recipients With BK Virus Reactivation. American Journal of Clinical Pathology, 2008, 129, 587-591.	0.7	41
78	THE CLINICAL SIGNIFICANCE OF CYTOMEGALOVIRAL INCLUSIONS IN THE ALLOGRAFT KIDNEY. Transplantation, 1999, 67, 98-103.	1.0	41
79	Antigen-Specificity of T Cell Infiltrates in Biopsies With T Cell–Mediated Rejection and BK Polyomavirus Viremia: Analysis by Next Generation Sequencing. American Journal of Transplantation, 2016, 16, 3131-3138.	4.7	39
80	Alemtuzumab Preconditioning With Tacrolimus Monotherapy—The Impact of Serial Monitoring for Donor-Specific Antibody. Transplantation, 2008, 85, 1125-1132.	1.0	38
81	Cytokine mRNA profiles in Epstein-Barr virus-associated post-transplant lymphoproliferative disorders. Clinical Transplantation, 1999, 13, 39-44.	1.6	37
82	VPâ€l quasispecies in human infection with polyomavirus BK. Journal of Medical Virology, 2012, 84, 152-161.	5.0	37
83	RENAL ALLOGRAFT REJECTION WITH NORMAL RENAL FUNCTION IN SIMULTANEOUS KIDNEY/PANCREAS RECIPIENTS. Transplantation, 2000, 69, 440-442.	1.0	36
84	Polyomavirus BK non-coding control region rearrangements in health and disease. Journal of Medical Virology, 2007, 79, 1199-1207.	5.0	35
85	T-cell-mediated rejection of the kidney in the era of donor-specific antibodies. Current Opinion in Organ Transplantation, 2015, 20, 325-332.	1.6	35
86	Detection of CD8+ T Cells Sensitized to BK Virus Large T Antigen in Healthy Volunteers and Kidney Transplant Recipients. Human Immunology, 2006, 67, 298-302.	2.4	34
87	Acute Renal Allograft Rejection With Severe Tubulitis (Banff 1997 Grade IB). American Journal of Surgical Pathology, 2000, 24, 553-558.	3.7	33
88	EPSTEIN-BARR VIRUS-ASSOCIATED LYMPHOPROLIFERATIVE DISEASE IN A HEART-LUNG ALLOGRAFT. Transplantation, 1990, 49, 126-129.	1.0	32
89	Antihuman Leukocyte Antigen–Specific Antibody Strength Determined by Complement-Dependent or Solid-Phase Assays Can Predict Positive Donor-Specific Crossmatches. Archives of Pathology and Laboratory Medicine, 2010, 134, 1534-1540.	2.5	32
90	Isolated Endarteritis and Kidney Transplant Survival. Journal of the American Society of Nephrology: JASN, 2015, 26, 1216-1227.	6.1	31

#	Article	IF	CITATIONS
91	Early subclinical tubulitis and interstitial inflammation in kidney transplantation have adverse clinical implications. Kidney International, 2020, 98, 436-447.	5.2	31
92	BK Virus: Discovery, Epidemiology, and Biology. Graft: Organ and Cell Transplantation, 0, 5, S19-S27.	0.0	31
93	Coordinated Circulating T Follicular Helper and Activated B Cell Responses Underlie the Onset of Antibody-Mediated Rejection in Kidney Transplantation. Journal of the American Society of Nephrology: JASN, 2020, 31, 2457-2474.	6.1	30
94	Defining housekeeping genes suitable for RNA-seq analysis of the human allograft kidney biopsy tissue. BMC Medical Genomics, 2019, 12, 86.	1.5	29
95	Experience With Liver And Kidney Allografts From Non-Heart-Beating Donors. Transplantation, 1995, 59, 197-203.	1.0	29
96	RECURRENT HEPATIC ALLOGRAFT INJURY IN ERYTHROPOIETIC PROTOPORPHYRIA1. Transplantation, 1996, 61, 1412,1413.	1.0	29
97	Allografts Surviving for 26 to 29 Years Following Living-Related Kidney Transplantation: Analysis by Light Microscopy, In Situ Hybridization for the Y Chromosome, and Anti-HLA Antibodies. American Journal of Kidney Diseases, 1994, 24, 72-77.	1.9	28
98	The significance of renal C4d staining in patients with BK viruria, viremia, and nephropathy. Modern Pathology, 2009, 22, 1468-1476.	5.5	28
99	Acute Renal Allograft Rejection: Diagnostic Significance of Focal Peritubular Capillary C4d. Transplantation, 2008, 85, 813-820.	1.0	27
100	HLA-A2, HLA-B44 and HLA-DR15 are associated with lower risk of BK viremia. Nephrology Dialysis Transplantation, 2013, 28, 3119-3126.	0.7	27
101	Allograft Liver Biopsy in Patients With Epstein-Barr Virus–Associated Posttransplant Lymphoproliferative Disease. American Journal of Surgical Pathology, 2001, 25, 324-330.	3.7	26
102	Identification of species-specific and cross-reactive epitopes in human polyomavirus capsids using monoclonal antibodies. Journal of General Virology, 2009, 90, 634-639.	2.9	26
103	Dexamethasone Increases Superoxide Dismutase Activity in Serum-Free Rat Fetal Lung Organ Cultures. Pediatric Research, 1986, 20, 895-898.	2.3	23
104	The Impact of Early Clinical and Subclinical T Cell–mediated Rejection After Kidney Transplantation. Transplantation, 2019, 103, 1457-1467.	1.0	23
105	Antirejection Treatment in Kidney Transplant Patients with BK Viruria. Transplantation, 2008, 86, 797-803.	1.0	22
106	The Polyomavirus BK Large T-Antigen-Derived Peptide Elicits an HLA-DR Promiscuous and Polyfunctional CD4 ⁺ T-Cell Response. Vaccine Journal, 2011, 18, 815-824.	3.1	22
107	SPONTANEOUS ARTERIOENTERIC FISTULA AFTER PANCREAS TRANSPLANTATION. Transplantation, 1997, 63, 903,904.	1.0	22
108	Clinicopathologic analysis of patients with BK viruria and rejection-like graft dysfunction. Human Pathology, 2009, 40, 1312-1319.	2.0	21

#	Article	IF	CITATIONS
109	Cadherin-11, Sparc-related modular calcium binding protein-2, and Pigment epithelium-derived factor are promising non-invasive biomarkers of kidney fibrosis. Kidney International, 2021, 100, 672-683.	5.2	21
110	Cidofovir: A Method of Treatment for BK Virus–Associated Transplant Nephropathy. Graft: Organ and Cell Transplantation, 0, 5, S82-S87.	0.0	21
111	T-bet+CD27+CD21– B cells poised for plasma cell differentiation during antibody-mediated rejection of kidney transplants. JCl Insight, 2021, 6, .	5.0	20
112	Histopathology of renal posttransplant lymphoproliferation: Comparison with rejection using the banff schema. American Journal of Kidney Diseases, 1996, 28, 578-584.	1.9	19
113	Cholesterol Embolization in Renal Allografts. American Journal of Surgical Pathology, 2007, 31, 536-545.	3.7	19
114	Intragraft gene expression in native kidney BK virus nephropathy versus T cell–mediated rejection: Prospects for molecular diagnosis and risk prediction. American Journal of Transplantation, 2020, 20, 3486-3501.	4.7	19
115	The Pathobiology of Polyomavirus Infection in Man. Advances in Experimental Medicine and Biology, 2006, 577, 148-159.	1.6	19
116	"STRIPED" PATTERN OF MEDULLARY RAY FIBROSIS IN ALLOGRAFT BIOPSIES FROM KIDNEY TRANSPLANT RECIPIENTS MAINTAINED ON TACROLIMUS1. Transplantation, 1999, 67, 484-486.	1.0	18
117	HLA-A01-, -A03-, and -A024-binding nanomeric epitopes in polyomavirus BK large T antigen. Human Immunology, 2009, 70, 722-728.	2.4	17
118	Occurrence of Urinary Tract Infection in Patients with Renal Allograft Biopsies Showing Neutrophilic Tubulitis. Modern Pathology, 2003, 16, 281-285.	5.5	16
119	Diagnosis of T-cell–mediated kidney rejection in formalin-fixed, paraffin-embedded tissues using RNA-Seq–based machine learning algorithms. Human Pathology, 2019, 84, 283-290.	2.0	16
120	Single versus dual renal transplantation from donors with significant arteriosclerosis on preâ€implant biopsy. Clinical Transplantation, 2009, 23, 525-531.	1.6	15
121	Neutrophilic Tubulitis as a Marker for Urinary Tract Infection in Renal Allograft Biopsies With C4d Deposition. Transplantation, 2009, 87, 1013-1018.	1.0	15
122	<i>Bartonella henselae</i> Endocarditis and Glomerulonephritis with Dominant C3 Deposition in a 21-Year-Old Male with a Melody Transcatheter Pulmonary Valve: Case Report and Review of the Literature. Pediatric and Developmental Pathology, 2014, 17, 312-320.	1.0	15
123	Early allograft inflammation and scarring associate with graft dysfunction and poor outcomes in renal transplant recipients with delayed graft function: a prospective single center cohort study. Transplant International, 2018, 31, 1369-1379.	1.6	15
124	Cellular and viral miRNA expression in polyomavirus BK infection. Transplant Infectious Disease, 2019, 21, e13159.	1.7	15
125	Detection of BKV encoded mature MicroRNAs in kidney transplant patients: Clinical and biologic insights. Journal of Clinical Virology, 2019, 119, 6-10.	3.1	15
126	CANDIDA ALBICANS OSTEOMYELITIS IN A LIVER TRANSPLANT RECIPIENT. Transplantation, 1996, 62, 1182-1184.	1.0	15

8

#	Article	IF	CITATIONS
127	Viral Drug Sensitivity Testing Using Quantitative PCR: Table 1. American Journal of Clinical Pathology, 2010, 134, 916-920.	0.7	14
128	Polyomavirus BK Nephropathy-Associated Transcriptomic Signatures: A Critical Reevaluation. Transplantation Direct, 2018, 4, e339.	1.6	13
129	Quantitative Proteomics for Monitoring Renal Transplant Injury. Proteomics - Clinical Applications, 2020, 14, e1900036.	1.6	13
130	The Potential Role of Cytokines in the Pathogenesis of Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disease. Leukemia and Lymphoma, 1994, 15, 383-387.	1.3	12
131	Anti-BK Virus Activity of Nucleoside Analogs. Antimicrobial Agents and Chemotherapy, 2008, 52, 1519-1521.	3.2	12
132	CLINICAL SIGNIFICANCE OF RENAL BIOPSIES SHOWING CONCURRENT ACUTE REJECTION AND TACROLIMUS-ASSOCIATED TUBULAR VACUOLIZATION1. Transplantation, 1999, 67, 85-89.	1.0	12
133	In vitro culture of B-lymphocytes derived from epstein-barr-virus-associated posttransplant lymphoproliferative disease: Cytokine production and effect of interferon-alpha. In Vitro Cellular and Developmental Biology - Animal, 1997, 33, 803-808.	1.5	11
134	Chronic Renal Failure After Liver Transplantation. American Journal of Transplantation, 2005, 5, 967-968.	4.7	11
135	Donor kidney microthrombi and outcomes of kidney transplant: a single-center experience. Clinical Transplantation, 2015, 29, 434-438.	1.6	11
136	Donor acute kidney injury and its effect on 1â€year postâ€transplant kidney allograft fibrosis. Clinical Transplantation, 2020, 34, e13770.	1.6	11
137	Concomitant loss of regulatory T and B cells is a distinguishing immune feature of antibody-mediated rejection in kidney transplantation. Kidney International, 2022, 101, 1003-1016.	5.2	11
138	A PROSPECTIVE RANDOMIZED TRIAL OF FK506-BASED IMMUNOSUPPRESSION AFTER RENAL TRANSPLANTATION1. Transplantation, 1995, 59, 485-490.	1.0	10
139	Renal Cortical Neoplasms In Long Term Survivors of Solid Organ Transplantation. Transplantation, 2000, 69, 864-869.	1.0	10
140	Interleukin-10 production by a B-cell line derived from human post-transplant lymphoproliferative disease. Hematological Oncology, 1995, 13, 13-18.	1.7	9
141	Conceptual Problems in the Diagnosis and Therapy of Acute Rejection in Patients with Polyomavirus Nephropathy. American Journal of Transplantation, 2004, 4, 840-840.	4.7	9
142	The molecular microscope diagnostic system (MMDx) in transplantation: A pathologist's perspective. American Journal of Transplantation, 2020, 20, 1965-1966.	4.7	9
143	Transcriptome and Exome Analyses of Hepatocellular Carcinoma Reveal Patterns to Predict Cancer Recurrence in Liver Transplant Patients. Hepatology Communications, 2022, 6, 710-727.	4.3	9
144	Kidney After Nonrenal Transplantation—The Impact of Alemtuzumab Induction. Transplantation, 2009, 88, 799-802.	1.0	8

#	Article	IF	CITATIONS
145	Determination of cidofovir in human plasma after low dose drug administration using high-performance liquid chromatography–tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2010, 53, 1015-1021.	2.8	8
146	Inhibition of large T antigen ATPase activity as a potential strategy to develop anti-polyomavirus JC drugs. Antiviral Research, 2014, 112, 113-119.	4.1	8
147	Deposition of Complement Product C4d in Anti–Glomerular Basement Membrane Glomerulonephritis. American Journal of Kidney Diseases, 2009, 53, 1098-1101.	1.9	7
148	Incorporation of Pathology and Laboratory Findings Into Management Algorithms for Polyomavirus Nephropathy. American Journal of Transplantation, 2013, 13, 1379-1381.	4.7	7
149	The Molecular Microscope (MMDX ^R) interpretation of thoracic and abdominal allograft biopsies: Putting things in perspective for the clinician. Clinical Transplantation, 2021, 35, e14223.	1.6	7
150	Cold Heparinized Lactated Ringers With Procaine (HeLP) Preservation Fluid in 266 Living Donor Kidney Transplantations. Transplantation, 2007, 83, 1134-1136.	1.0	6
151	Clinical course of kidney transplant patients with acute rejection and BK virus replication following Campath therapy. Clinical Transplantation, 2008, 22, 348-353.	1.6	6
152	Precision transplant pathology. Current Opinion in Organ Transplantation, 2020, 25, 412-419.	1.6	6
153	Subcutaneous implantation of human post-transplant lymphoproliferative disease lesions in SCID mice. , 1997, 15, 39-46.		5
154	The "Borderline―Renal Allograft Biopsy in the Era of Molecular Diagnostics: A Sampling Conundrum?. American Journal of Transplantation, 2012, 12, 11-12.	4.7	5
155	Patient perspectives and involvement in precision medicine research. Kidney International, 2021, 99, 511-514.	5.2	5
156	Kaposi's sarcoma in two primary liver allograft recipients occurring under FK506 immunosuppression. Clinical Transplantation, 1993, 7, 188-194.	1.6	5
157	Consensus Definitions of BK Polyomavirus Nephropathy in Renal Transplant Recipients for Clinical Trials. Clinical Infectious Diseases, 2022, 75, 1210-1216.	5.8	5
158	EBER Gene Expression in Epstein-Barr Virus-Associated Hematopoietic Neoplasms. Leukemia and Lymphoma, 1994, 13, 387-392.	1.3	4
159	BK Virus Replication In Vitro: Limited Effect of Drugs Interfering with Viral Uptake and Intracellular Transport. Antimicrobial Agents and Chemotherapy, 2007, 51, 4492-4494.	3.2	4
160	Validation of BKV large T-antigen ATP-binding site as a target for drug discovery. Antiviral Research, 2009, 81, 184-187.	4.1	4
161	A Case of Late Kidney Allograft Failure. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1884-1889.	4.5	4
162	Screening for BK polyomavirus DNAemia: What should be done?. Clinical Transplantation, 2019, 33, e13672.	1.6	4

10

#	Article	IF	CITATIONS
163	Role of Preimplantation Biopsies in Kidney Donors With Acute Kidney Injury. Transplantation, 2019, 103, 1752-1753.	1.0	4
164	The expanding spectrum of antibody-mediated rejection: Should we include cases where no anti-HLA donor-specific antibody is detected?. American Journal of Transplantation, 2019, 19, 622-624.	4.7	4
165	Chronic transplant glomerulopathy: New insights into pathogenesis. Clinical Transplantation, 2021, 35, e14214.	1.6	4
166	The MMDx [®] diagnostic system: A critical reâ€appraisal of its knowledge gaps and a call for rigorous validation studies. Clinical Transplantation, 2022, 36, .	1.6	4
167	Rejection of the Renal Allograft in the Absence of Demonstrable Antibody and Complement. Transplantation, 2017, 101, 395-401.	1.0	3
168	Evaluation of the Gastrointestinal Tract as Potential Route of Primary Polyomavirus Infection in Mice. PLoS ONE, 2016, 11, e0150786.	2.5	2
169	Fever and Gross Hematuria in Kidney TransplantÂRecipient. American Journal of Kidney Diseases, 2018, 72, A15-A18.	1.9	2
170	Acute right ventricular failure in a patient with nonischemic cardiogenic shock on leftâ€sided mechanical circulatory support. Journal of Cardiac Surgery, 2021, 36, 3884-3888.	0.7	2
171	Outcome of kidney transplantation under tacrolimus-based immunosuppression in elderly patients. Journal of Transplant Coordination, 1999, 9, 101-103.	0.2	2
172	BK VIRUS MUTATIONS IN POLYOMA VIRUS INTERSTITIAL NEPHRITIS AFTER RENAL TRANSPLANTATION Transplantation, 2000, 69, S137.	1.0	1
173	Donation after circulatory death is associated with increased fibrosis on 1â€year postâ€transplant kidney allograft surveillance biopsy. Clinical Transplantation, 2021, 35, e14399.	1.6	1
174	Co-administration of Co-trimoxazole Does Not Augment Tacrolimus-Induced Impairment in Kidney Function in Rats. Renal Failure, 1999, 21, 635-645.	2.1	0
175	DEVELOPMENT OF QUANTITATIVE PCR FOR BK VIRUS DETECTION IN URINE AND ITS ROLE IN MANAGEMENT OF ALLOGRAFT VIRAL INFECTION MASQUERADING AS ACUTE REJECTION Transplantation, 2000, 69, S136-S137.	1.0	0
176	Application of RNA-seq Derived Diagnostic Algorithms of T-cell Mediated Kidney Rejection (TCMR) to Publicly Available DNA Microarray-based Gene Expression Datasets. Transplantation, 2018, 102, S26.	1.0	0
177	Clinical correlates of glomerular infection by polyomavirus BK. Kidney International, 2018, 94, 1024.	5.2	0
178	CORTICAL SCARRING AS A VARIABLE IN THE ASSESSMENT OF DONOR KIDNEY BIOPSY SPECIMENS. Transplantation, 2001, 71, 1184.	1.0	0
179	Risk Factors for BK Viruria and Hemorrhagic Cystitis in Hematopoietic Stem Cell Transplant (HSCT) Recipients Blood, 2007, 110, 1072-1072.	1.4	0
180	MO942: Regulatory T and B Cell Responses are Equally Compromised During Antibody-Mediated Rejection of Kidney Allografts. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0